| Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants | Olanzapine | Phase 1 | Not yet recruiting | Neurelis, Inc. | Nov 6, 2026 |
| Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy | Olanzapine | Phase 2 | Not yet recruiting | Fudan University | Nov 5, 2026 |
| Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer | Olanzapine | Phase 2 | Not yet recruiting | Washington University School of Medicine | Nov 3, 2026 |
| Real-World Impact of TV-44749 in Adults With Schizophrenia | Olanzapine | — | Not yet recruiting | Teva Branded Pharmaceutical Products R&D LLC | Nov 3, 2026 |
| Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder | Haloperidol decanoate, Haloperidol | — | Recruiting | Bosnalijek D.D | Oct 5, 2026 |
| Safety, Tolerability, and Pharmacokinetics of DM1001 Transdermal Patch in Healthy Chinese Participants | Pramipexole | Phase 1 | Not yet recruiting | The Third Xiangya Hospital of Central South University | Sep 28, 2026 |
| Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors | Olanzapine | Phase 2 | Active, not recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Sep 25, 2026 |
| Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant | Olanzapine | Not applicable | Enrolling by invitation | Xiao Wang | Aug 5, 2026 |
| Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors | Olanzapine | Not applicable | Recruiting | Alexandria University | Aug 4, 2026 |
| Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department | Haloperidol decanoate, Haloperidol | Early phase 1 | Not yet recruiting | University of Illinois Chicago | Jul 24, 2026 |
| A Nutrition and Exercise Program With Olanzapine Compared to Olanzapine Alone: A Trial in Patients With Advanced Tumors | Olanzapine | Phase 2 | Not yet recruiting | Kantonsspital Winterthur KSW | Jul 23, 2026 |
| The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals | Apomorphine | Not applicable | Enrolling by invitation | University of Copenhagen | Jul 7, 2026 |
| Pramipexole vs Placebo Treatment in Bipolar Disorder With Anhedonic Depression | Pramipexole | Phase 3 | Recruiting | Daniel Lindqvist | Jun 24, 2026 |
| TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients | Droperidol | Not applicable | Recruiting | Zhejiang University | Mar 18, 2026 |
| SAD Study in Patients With Parkinson's Disease and Motor Fluctuations | Apomorphine | Phase 1 | Recruiting | Serina Therapeutics | Feb 20, 2026 |
| Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease | Apomorphine | — | Recruiting | Danish Research Centre for Magnetic Resonance | Feb 11, 2026 |
| Pramipexole and the Risk of Serious Adverse Events | Pramipexole | — | Active, not recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Feb 3, 2026 |
| Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy. | Chlorpromazine | Not applicable | Not yet recruiting | Ji Xunming,MD,PhD | Jan 23, 2026 |
| Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life | Apomorphine | — | Recruiting | Centre Hospitalier Régional d'Orléans | Dec 2, 2025 |
| Single-dose,First-in-human of KLA478 | Pramipexole | Phase 1 | Recruiting | Hunan Kelun Pharmaceutical Co., Ltd. | Nov 21, 2025 |
| Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: | Apomorphine | — | Recruiting | Supernus Pharmaceuticals, Inc. | Oct 22, 2025 |
| SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment | Apomorphine | — | Recruiting | Bial - Portela C S.A. | Aug 28, 2025 |
| A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets | Bromocriptine | Phase 3 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | Aug 15, 2025 |
| Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect? | Haloperidol decanoate, Haloperidol | Phase 4 | Recruiting | Centre for Addiction and Mental Health | Aug 7, 2025 |
| Stratified Pharmacological Approaches for Regulating Circuit-Level Effects | Pramipexole | Phase 2 | Recruiting | Stanford University | Jun 15, 2025 |
| Assessment of Drug Liking In Peri-procedural Clinical Settings | Droperidol | Early phase 1 | Enrolling by invitation | Stanford University | Jun 11, 2025 |
| Adhesion and Safety of Rotigexole Compared to Neupro® | Rotigotine | Not applicable | Not yet recruiting | Eva Pharma | Jun 11, 2025 |
| Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia | Trifluoperazine | Phase 2 / Phase 3 | Recruiting | Md. Moktadirul Hoque Shuvo | Jun 6, 2025 |
| Comparison of Haloperidol and Dexmedetomidine for Delirium and Agitation in ICU Patients With Traumatic Brain Injury | Haloperidol decanoate, Haloperidol | Not applicable | Not yet recruiting | Benha University | May 28, 2025 |
| Supra Inguinal Fascia Iliaca Block as Rescue Analgesia Following Total Hip Arthroplasty | Droperidol | Not applicable | Recruiting | Institut Mutualiste Montsouris | May 21, 2025 |
| Droperidol and QTc Interval Changes in ED Patients | Droperidol | — | Recruiting | CHRISTUS Health | Dec 10, 2024 |
| A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease | Rotigotine | Phase 3 | Recruiting | I.R.C.C.S. Fondazione Santa Lucia | Nov 22, 2024 |
| Study on Hibernation-like Therapy Based on Mechanical Thrombectomy | Chlorpromazine | Phase 1 | Recruiting | Capital Medical University | Oct 29, 2024 |
| Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD) | Pramipexole | Phase 2 | Recruiting | Clinical Academic Center (2CA-Braga) | Sep 25, 2024 |
| Precision Care for Major Depressive Disorder | Pramipexole | Phase 4 | Enrolling by invitation | University of California, San Francisco | Aug 30, 2024 |
| Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma | Bromocriptine | Not applicable | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | Aug 15, 2024 |
| A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD | Pramipexole | Phase 2 | Active, not recruiting | Areteia Therapeutics | Aug 1, 2024 |
| Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department | Haloperidol decanoate, Haloperidol | Phase 4 | Recruiting | Western Michigan University School of Medicine | May 2, 2024 |
| Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease | Rotigotine | Phase 2 | Recruiting | University Hospital, Rouen | Mar 4, 2024 |
| Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age | Bromocriptine | Phase 3 | Recruiting | Jimma University | Feb 9, 2024 |
| The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM | Haloperidol decanoate, Haloperidol | Phase 2 | Not yet recruiting | Southern Medical University, China | Jan 23, 2024 |
| Maternal And Infant Antipsychotic Study | Haloperidol decanoate, Haloperidol | — | Recruiting | Icahn School of Medicine at Mount Sinai | Sep 22, 2023 |
| The Danish Out-of-Hospital Cardiac Arrest Study | Haloperidol decanoate, Haloperidol | Phase 3 | Active, not recruiting | Christian Hassager | Jun 9, 2023 |
| Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy | Chlorpromazine | Phase 2 / Phase 3 | Active, not recruiting | M.D. Anderson Cancer Center | Jun 24, 2022 |
| Apomorphine in Severe Brain-injured Patients | Apomorphine | Phase 2 / Phase 3 | Recruiting | University of Liege | Jan 28, 2022 |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Bromocriptine | Phase 4 | Recruiting | Dennis M. McNamara, MD, MS | Jan 6, 2022 |
| Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump) | Apomorphine | — | Not yet recruiting | University Hospital, Strasbourg, France | Oct 8, 2021 |
| Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair | Droperidol | Phase 4 | Recruiting | University of Crete | May 20, 2021 |
| Bromocriptine for Patients With Schizophrenia and Prediabetes | Bromocriptine | Phase 4 | Not yet recruiting | VA Pittsburgh Healthcare System | Jul 2, 2018 |
| Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer | Chlorpromazine | Phase 2 / Phase 3 | Active, not recruiting | M.D. Anderson Cancer Center | Jan 16, 2017 |
| Gait Analysis in Neurological Disease | Ropinirole | — | Active, not recruiting | Beth Israel Deaconess Medical Center | Dec 16, 2016 |
| Quality Improvement and Practice Based Research in Neurology Using the EMR | Rotigotine | Phase 4 | Enrolling by invitation | Endeavor Health | Feb 1, 2016 |
| Infusion of Apomorphine: Long-term Safety Study | Ropinirole, Rotigotine | Phase 3 | Active, not recruiting | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Jan 15, 2015 |